Search

Your search keyword '"Ceparano, Giusy"' showing total 9 results
Start Over Author "Ceparano, Giusy"
9 results on '"Ceparano, Giusy"'

3. Demystifying the diagnostic criteria of indolent systemic mastocytosis

Author

Grifoni, Federica Irene, primary, Sciumè, Mariarita, additional, Ceparano, Giusy, additional, Lavezzari, Marco, additional, Galassi, Giulia, additional, Pravettoni, Valerio, additional, Eller‐Vainicher, Cristina, additional, Muratori, Simona, additional, Fabris, Sonia, additional, Gianelli, Umberto, additional, Giannarelli, Diana, additional, and Baldini, Luca, additional

Published
2021
Full Text
View/download PDF

6. Prognostic Impact of the Baseline Immunologic Profile in Patients with Aggressive B Non-Hodgkin Lymphomas

Author

Ramadan, Safaa M., primary, Ceparano, Giusy, additional, Cignetti, Alessandro, additional, Sammassimo, Simona, additional, Bagnardi, Vincenzo, additional, Pagan, Eleonora, additional, Gottardi, Daniela, additional, Fiori, Stefano, additional, Passerini, Rita, additional, Radice, Tommaso, additional, Saglio, Giuseppe, additional, and Tarella, Corrado, additional

Published
2019
Full Text
View/download PDF

7. B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Author

Ramadan, Safaa M., primary, Cignetti, Alessandro, additional, Sammassimo, Simona, additional, Derenzini, Enrico, additional, Ceparano, Giusy, additional, Radice, Tommaso, additional, Gigli, Federica, additional, Fiori, Stefano, additional, Tabanelli, Valentina, additional, Milani, Martina, additional, Omodeo Sale', Emanuela, additional, Gandini, Sara, additional, Gottardi, Daniela, additional, Saglio, Giuseppe, additional, Pileri, Stefano, additional, and Tarella, Corrado, additional

Published
2019
Full Text
View/download PDF

8. Demystifying the diagnostic criteria of indolent systemic mastocytosis.

Author

Grifoni, Federica Irene, Sciumè, Mariarita, Ceparano, Giusy, Lavezzari, Marco, Galassi, Giulia, Pravettoni, Valerio, Eller‐Vainicher, Cristina, Muratori, Simona, Fabris, Sonia, Gianelli, Umberto, Giannarelli, Diana, and Baldini, Luca

Subjects
MAST cell disease, BONE marrow cells
Abstract

Herein, we report our monocentric experience, as SM referral Centre, about ISM and "pre-diagnostic ISM", which we defined as MMAS or cutaneous mastocytosis with MC clonality which does not fulfill all SM diagnostic criteria. Keywords: diagnosis; diagnostic criteria; systemic mastocytosis EN diagnosis diagnostic criteria systemic mastocytosis 122 124 3 02/07/22 20220201 NES 220201 DATA AVAILABILITY STATEMENT All data are available from the corresponding author on reasonable request. At diagnosis, median age was 51 years (range 22-86) for ISM and 49 years (range 22-74) for "pre-diagnostic ISM"; the median symptom durations before diagnosis were 9 and 7 years for ISM and "pre-diagnostic ISM", respectively. [Extracted from the article]

Published
2022
Full Text
View/download PDF

9. Prognostic Impact of Baseline Immunologic Profile in Aggressive B-cell non-Hodgkin's Lymphomas.

Author

Ramadan, Safaa, Ceparano, Giusy, Cignetti, Alessandro, Sammassimo, Simona, Bagnardi, Vincenzo, Pagan, Eleonora, Gottardi, Daniela, Fiori, Stefano, Passerini, Rita, Radice, Tommaso, Saglio, Giuseppe, and Tarella, Corrado

Subjects
*MONOCYTE lymphocyte ratio, *LYMPHOMAS, *NON-Hodgkin's lymphoma, *IMMUNOGLOBULINS
Abstract

Host immune homeostasis as an independent prognostic indicator has been inadequately evaluated in aggressive non-Hodgkin's lymphomas (NHL). The present study addresses the prognostic significance in aggressive NHLs of the immunologic profile evaluated by pretreatment serum levels of immunoglobulins (Ig) and lymphocyte-monocyte ratio (LMR). In this series of 90 patients with aggressive lymphoma, the median level for IgG was 1,024mg/dl (range 436-2236), and for LMR was 2.2 (range 0.2-13.8). CR rate was higher with IgG levels =1,024mg/dL (91% vs 77% p=0.059). LMR = 2.2 was associated with lower 1-year PFS (73% vs. 92%, p 0.016). Patients with good/very good R-IPI showed a reduced PFS if IgG or LMR was low, while patients with poor R-IPI did better if LMR or IgG levels were high. We combined both parameters with the RIPI and produced a four-risk prognostic score showing one-year PFS of 95% (95% CI 68%-99%), 100% (95% CI 100%-100%), 73% (95% CI 52%-86%), and 59% (95% CI 31%-79%), in patients with zero, one, two and three risk factors, respectively. The results indicate for the first time the value of baseline serum Ig levels in the prognostic assessment of aggressive lymphoma. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results